Impact of Social Distancing Measures, Expansion of Telemedicine for Buprenorphine Prescribing, and Health Insurance Payor on Access to Buprenorphine During the COVID-19 Pandemic

COVID-19-related social distancing has resulted in disruptions in the delivery of health care. Simultaneously, the synergistic epidemic between the opioid overdose crisis and the COVID-19 pandemic has resulted in major regulatory changes to ease access to medications for opioid use disorder (MOUD) via telemedicine. This study seeks to address the priorities of NIDA by analyzing a dataset with >90% of all US prescriptions to examine the time-varying impact of COVID-19-related social distancing, MOUD prescribing guideline changes, and health insurance on access to buprenorphine.

CTN Protocol ID: 
CTN-0119
Status: 
Active

Principal Investigator(s)

Jane Liebschutz, M.D., M.P.H., FACP

Chief, Division of General Internal Medicine
University of Pittsburgh School of Medicine
UPMC Health System

200 Lothrop Street, Suite 933W
Pittsburgh, PA 15213
United States